TRAWS PHARMA ($TRAW) posted quarterly earnings results for Q4 2025 on Wednesday, April 15th. The company reported earnings of -$0.71 per share, beating estimates of -$1.25 by $0.54. The company also reported revenue of $0, equaling estimates of $0 by $0.
Stock price change since market close: -6.03%
You can see Quiver Quantitative's $TRAW stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
TRAWS PHARMA Hedge Fund Activity
We have seen 11 institutional investors add shares of TRAWS PHARMA stock to their portfolio, and 7 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- IKARIAN CAPITAL, LLC added 649,649 shares (+2280.0%) to their portfolio in Q4 2025, for an estimated $734,103
- BOOTHBAY FUND MANAGEMENT, LLC added 194,536 shares (+inf%) to their portfolio in Q4 2025, for an estimated $219,825
- ADAR1 CAPITAL MANAGEMENT, LLC added 154,431 shares (+inf%) to their portfolio in Q4 2025, for an estimated $174,507
- VESTAL POINT CAPITAL, LP removed 150,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $169,499
- XTX TOPCO LTD added 31,502 shares (+294.2%) to their portfolio in Q4 2025, for an estimated $35,597
- STATE STREET CORP added 25,802 shares (+inf%) to their portfolio in Q4 2025, for an estimated $29,156
- CITADEL ADVISORS LLC added 24,819 shares (+inf%) to their portfolio in Q4 2025, for an estimated $28,045
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
